Stock Analysis
Corcept Therapeutics Inc.CORT
P/E 215.80×· not meaningful — TTM earnings temporarily depressed
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy12 analystsPrice is 85% of the way from the year's low to its high.
Cash covers 3271% of debt · Q2 2026.
PMP Verdict
Mixed fundamentals, expensive valuation
Strengths
- Financial Health100
- Quality77
Risks
- Valuation10
- Profitability28
Mixed fundamentals at a demanding price.
Market context
-2.8% today· Z 1.3σ
Bull Case
- ✓Altman Z 43.8 — safe-zone balance sheet
- ✓Revenue CAGR 20.1% — durable top-line growth
- ✓Interest coverage 106.6× — debt well covered
What's happening with CORT
Profile
Strong financial health, moat and earnings quality; valuation and profitability lag behind.
How is each axis scored?
- Valuation10/100 · Weak
- P/E vs own history (96th pct)0/25
- FCF yield (0.9%)5/25
- P/S (14.3x)5/25
- EV/EBIT (1806.6x)0/25
- Growth50/100 · Moderate
- Revenue CAGR (20.1%)25/25
- Net income CAGR (-3.0%)0/25
- EPS CAGR 5Y (-1.8%)0/25
- Fwd implied growth (545.7%)25/25
- Profitability28/100 · Weak
- ROIC (1.2%)5/25
- ROE (7.8%)5/25
- Net margin (6.6%)13/25
- Operating margin (0.8%)5/25
- Financial Health100/100 · Strong
- Altman Z (43.79)25/25
- Current ratio (2.86)25/25
- Interest coverage (106.6x)25/25
- Net cash / debt (Net cash)25/25
- Quality77/100 · Strong
- Piotroski F (5/9)15/25
- Beneish M (-2.69)25/25
- FCF conversion (194%)25/25
- Margin stability (σ 14.1%)12/25
- Moat100/100 · Strong
- ROIC >12% years (9/9 yrs)25/25
- Median gross margin (98.3%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 10.0%)25/25
Risk Flags
- ⚠SBC 11.6% of revenue — real dilution cost
About Corcept Therapeutics Inc.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. Show more
The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Headquarters: REDWOOD CITY, CA · Employees: 730 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
10EP/E (TTM)215xC
Grade C: DistortedTTM earnings are temporarily depressed — this multiple overstates expensiveness. Forward P/E is a better guide — vs own 5Y history: 17.8x–242.9x · 96th pct
P/FCF100.3xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield0.9%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 0.8%–8.9% · 4th pct
P/S (TTM)14.29xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 4.7x–20.0x · 95th pct
EV/EBIT1806.6xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 1400.7x–2035.4x · 31st pct
EV/Sales14.8xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E33.3xC
Grade C: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio16.82xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio—
Finnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
28EROIC1.2%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE7.8%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA6.6%C
Grade C: AverageReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin6.6%C
Grade C: AverageNet Income / Revenue
Operating Margin0.8%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin98.3%A
Grade A: PremiumGross Profit / Revenue
FCF Margin12.9%C
Grade C: AverageFCF / Revenue
True FCF Margin1.3%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
50CRevenue CAGR20.1%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-3.0%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-1.8%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth545.7%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-15.7%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income174.2%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue11.6%D
Grade D: HighTTM stock-based comp / TTM Revenue
Financial Health
100A+Altman Z-Score43.79A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.86xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio2.63xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage106.6xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBITNet CashA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.01xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt32.71xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
77B+Piotroski F-Score5/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.69A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion193.8%A
Grade A: StrongFCF / Net Income
Margin Stability14.1%C
Grade C: AverageEBIT margin std deviation. Lower = stable
Capex / Revenue0.3%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.99xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Vieira Roberto Wandenkolk Filed | Vieira Roberto Wandenkolk | Option exercise | -8333 | |
Vieira Roberto Wandenkolk Filed | Vieira Roberto Wandenkolk | SellOpen market sale | -5147 | |
Vieira Roberto Wandenkolk Filed | Vieira Roberto Wandenkolk | SellOpen market sale | -2086 | |
Vieira Roberto Wandenkolk Filed | Vieira Roberto Wandenkolk | SellOpen market sale | -1100 | |
Vieira Roberto Wandenkolk Filed | Vieira Roberto Wandenkolk | Option exercise | +8.3K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Lyon Joseph Douglas Filed | Lyon Joseph Douglas | Option exercise | -5833 | |
Lyon Joseph Douglas Filed | Lyon Joseph Douglas | Option exercise | -3357 | |
Lyon Joseph Douglas Filed | Lyon Joseph Douglas | SellOpen market sale | -4744 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
100A+ROIC >12% Years9/9 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)98.3%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor10.0%A
Grade A: DurableWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$0.51
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$2.92
Cash & short-term investments per share (Finnhub)
Book Value / Share$6.54
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$9.42M
Total debt obligations (short + long term)
Cash & Equiv.$308.20M
Cash and short-term investments
Net Debt$-298.78MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$705.78M
Shareholders' equity (book value)
Asset / Liability4.86xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$11.87B
Current Market Capitalization
Beta0.52B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Corcept Therapeutics Inc. (CORT)
CORT is down 2.83% at the last close. Piotroski F-Score of 5/9 indicates mixed fundamentals for Corcept Therapeutics Inc.. Altman Z-Score of 43.79 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.69 suggests a low likelihood of earnings manipulation.
- Revenue has compounded at roughly 20% annually — a strong growth profile.
- Company is effectively debt-free after netting cash.
- At a valuation score of 10/100, CORT trades at a premium to its historical multiples (P/E 215.2).
See how CORT ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all CORT moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 5 | Regular | 122.25 | +5.18% | 2.04 |
| Oct 5 | After-hours | 123.04 | +5.86% | 2.32 |
| Sep 24 | Regular | 118.50 | +4.92% | 2.27 |
| Sep 24 | After-hours | 118.00 | +4.48% | 2.08 |
| Sep 22 | Regular | 118.20 | +3.90% | 2.09 |
Frequently Asked Questions about CORT
What is the current Corcept Therapeutics Inc. (CORT) stock price?
CORT is trading at $110.16 at the last market close, down 2.83% on the session. PreMarketPrice tracks CORT pre-market, intraday and after-hours prices.
Is CORT stock a buy right now?
PreMarketPrice's quantitative model rates Corcept Therapeutics Inc.'s financial health at 100/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is CORT stock overvalued?
Corcept Therapeutics Inc. trades at a trailing P/E of 215.2 and our valuation score rates it 10/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Corcept Therapeutics Inc. report earnings?
No confirmed earnings date is currently scheduled for CORT. The Earnings section lists recent reports and updates as dates are announced.
What sector does Corcept Therapeutics Inc. operate in?
Corcept Therapeutics Inc. operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Corcept Therapeutics Inc. do?
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone.
About Corcept Therapeutics Inc. (CORT) Stock
Corcept Therapeutics Inc. (CORT) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. As of the latest update, Corcept Therapeutics Inc. is trading at $110.16, down 2.83% on the day with a market capitalization of $11.9 billion. The financial health score for CORT is 100/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for CORT stock.
CORT Stock Analysis & Key Metrics
On PreMarketPrice, you can track Corcept Therapeutics Inc. (CORT) across multiple dimensions:
- Pre-market price & movement: Real-time CORT stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for CORT with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Corcept Therapeutics Inc. across multiple reporting periods.
- Financial health score: A composite score of 100/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for CORT.
- Sector peers: Compare CORT against 6 other healthcare stocks on key financial metrics.
Is CORT a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Corcept Therapeutics Inc. (CORT) as an investment. The financial health score of 100/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Corcept Therapeutics Inc. (CORT) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.